# David B. Singer
David B. Singer is a venture capital investor, managing partner at Maverick Ventures, where he has led the firm's private investments since 2004.[1](https://www.forbes.com/profile/david-b-singer/) • [2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) He is best known for One Medical, the primary-care company Amazon acquired in February 2023 for $3.9 billion.[1](https://www.forbes.com/profile/david-b-singer/) In 2023 and 2024 he was included in Forbes' Midas List of the world's best venture capital investors.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) Before becoming an investor he was the founding chief executive of three life-sciences companies: [Affymetrix](https://www.edgepedia.org/affymetrix), Corcept Therapeutics, and Genesoft Pharmaceuticals.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer)
| Fact | Detail |
| --- | --- |
| Role | Managing partner, Maverick Ventures, leading private investments since 2004[1](https://www.forbes.com/profile/david-b-singer/) • [3](https://maverick-capital-ventures.webflow.io/) |
| Prior career | Founding CEO of Affymetrix (NASDAQ: AFFX), Corcept Therapeutics (NASDAQ: CORT), and Genesoft Pharmaceuticals (NASDAQ: OSCI)[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) |
| Education | BA in History, Yale University, 1984; MBA, Stanford Graduate School of Business, 1988[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) |
| Best-known deal | One Medical, acquired by Amazon for $3.9 billion, February 2023[1](https://www.forbes.com/profile/david-b-singer/) |
| Other investments | Seer, Devoted Health ($12.9B valuation), Coupang, BioCatch, MosaicML[1](https://www.forbes.com/profile/david-b-singer/) • [4](https://seedlist.com/investors/david-singer.html) |
| Recognition | Forbes Midas List 2023 and 2024[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) |
| Fund size | $600 million third evergreen fund, raised April 2021[5](https://www.forbes.com/sites/alexkonrad/2021/04/12/maverick-ventures-600m-third-evergreen-fund/) |
| Civic roles | Vice Chair of College Track; Sterling Fellow of Yale; former Vice President of the San Francisco Health Commission[3](https://maverick-capital-ventures.webflow.io/) • [6](https://ventures.yale.edu/our-team/david-singer-mba) |
## Education and academic roles
Singer earned a BA in History from Yale University in 1984 and an MBA from the [Stanford Graduate School of Business](https://www.edgepedia.org/stanford-graduate-school-of-business) in 1988.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) He later returned to Stanford GSB as a Lecturer, and Yale lists him as a Sterling Fellow of the university.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) • [6](https://ventures.yale.edu/our-team/david-singer-mba)
## Career before Maverick
Prior to joining Maverick, Singer served as the founding CEO of three companies: Affymetrix (NASDAQ: AFFX), a pioneer in DNA chip technology; Corcept Therapeutics (NASDAQ: CORT); and Genesoft Pharmaceuticals (NASDAQ: OSCI).[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer)
In 2004 Singer joined [Maverick Capital](https://www.edgepedia.org/maverick-capital), the hedge fund founded by [Tiger Management](https://www.edgepedia.org/tiger-management) alum [Lee Ainslie](https://www.edgepedia.org/lee-ainslie), to build and lead its private-investment practice; he has led Maverick's private investments since that time.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) • [5](https://www.forbes.com/sites/alexkonrad/2021/04/12/maverick-ventures-600m-third-evergreen-fund/) • [3](https://maverick-capital-ventures.webflow.io/)
## Maverick Ventures and the evergreen model
Maverick Ventures is the venture arm of Maverick Capital, formally established as a named vehicle in 2015.[3](https://maverick-capital-ventures.webflow.io/) In April 2021 the firm raised a $600 million third evergreen fund.[5](https://www.forbes.com/sites/alexkonrad/2021/04/12/maverick-ventures-600m-third-evergreen-fund/) The firm's materials describe an evergreen structure that supports entrepreneurs for an indefinite time horizon, rather than the fixed ten-year life of a conventional venture fund.[3](https://maverick-capital-ventures.webflow.io/) Singer has cited [Sutter Hill Ventures](https://www.edgepedia.org/sutter-hill-ventures), an early backer of his own company Corcept, as the inspiration for the evergreen approach.[5](https://www.forbes.com/sites/alexkonrad/2021/04/12/maverick-ventures-600m-third-evergreen-fund/) In a 2025 Fortune interview, as quoted by Seedlist, he described the hands-on posture that comes with it: "We think about this as a full-contact sport. Once we invest, we're in it."[4](https://seedlist.com/investors/david-singer.html)
## Notable investments and exits
**One Medical.** Singer joined the board of the primary-care provider One Medical in September 2011 and served through the acquisition by Amazon in February 2023 for $3.9 billion, roughly twelve years of board service on a single exit.[4](https://seedlist.com/investors/david-singer.html) • [1](https://www.forbes.com/profile/david-b-singer/) Forbes names it his most notable deal.[1](https://www.forbes.com/profile/david-b-singer/)
**Healthcare and sequencing.** He was a founding investor in proteomics company Seer, which went public in 2020, and invested in [Devoted Health](https://www.edgepedia.org/devoted-health) at a $12.9 billion valuation.[1](https://www.forbes.com/profile/david-b-singer/) Earlier deals include [Pacific Biosciences](https://www.edgepedia.org/pacific-biosciences) (around 2007) and Castlight Health (2010).[4](https://seedlist.com/investors/david-singer.html)
**Commerce and software.** His investments include Coupang (around 2014), Cityblock Health (2018 Series A lead), and Hims & Hers (2018 Series B).[4](https://seedlist.com/investors/david-singer.html)
**Post-2023 exits.** BioCatch, where Maverick led a 2018 Series B, was acquired by Permira for $1.3 billion in 2024; MosaicML, entered around 2021, was acquired by [Databricks](https://www.edgepedia.org/databricks) for $1.3 billion in 2023.[4](https://seedlist.com/investors/david-singer.html)
## Investment focus
Singer's stated focus is [DNA sequencing](https://www.edgepedia.org/dna-sequencing) tools, eCommerce, and digital health.[1](https://www.forbes.com/profile/david-b-singer/) The focus tracks his operating record: as a three-time founding CEO in biotech and pharmaceuticals, he has run the kinds of companies he now funds.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) The deal record skews healthcare, with 10 of 15 verified investments in healthcare or health technology against 3 in enterprise software and AI, spanning seed through Series B.[4](https://seedlist.com/investors/david-singer.html)
## Boards and public positions
According to Forbes' 2025 Midas profile, Singer serves on the boards of Generate Security, Infleqtion, LTK, Oula, SpearBio, Tata 1MG, and Volta Labs, and is a board observer for Mon Ami and [Collective Health](https://www.edgepedia.org/collective-health).[1](https://www.forbes.com/profile/david-b-singer/) A 2026 SEC Form 4 corroborates the [Infleqtion](https://www.edgepedia.org/infleqtion) seat: on April 10, 2026 he was awarded 33,928 stock options in Infleqtion, Inc.[7](https://www.sec.gov/cgi-bin/own-disp?CIK=0001240366&action=getowner&sortid=filings-ASC) Yale Ventures lists him on the board of Castlight Health (NYSE: CSLT).[6](https://ventures.yale.edu/our-team/david-singer-mba)
Past board service includes Affymetrix, Corcept Therapeutics, CoreValve, Coupang, One Medical, Pacific BioSciences, and Seer.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer) Beyond company boards, he is Vice Chair of College Track, a former Aspen Institute Crown Fellow, a former member of the Rand Corporation's Health Advisory Board, and was formerly Vice President of the San Francisco Health Commission.[3](https://maverick-capital-ventures.webflow.io/) • [2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer)
## Recognition: the Midas List
Singer appeared on the Forbes Midas List of venture investors in 2023 and 2024.[2](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer)
## References
1. [David B. Singer — Forbes Midas List profile](https://www.forbes.com/profile/david-b-singer/)
2. [David Byrd Singer — Stanford Graduate School of Business](https://www.gsb.stanford.edu/faculty-research/faculty/david-byrd-singer)
3. [Maverick Ventures — firm team page](https://maverick-capital-ventures.webflow.io/)
4. [David Singer — Seedlist.com](https://seedlist.com/investors/david-singer.html)
5. [Fresh Off Coupang Exit, Maverick Ventures Adds $600 Million Third Evergreen Fund — Forbes](https://www.forbes.com/sites/alexkonrad/2021/04/12/maverick-ventures-600m-third-evergreen-fund/)
6. [David Singer, M.B.A. — Yale Ventures](https://ventures.yale.edu/our-team/david-singer-mba)
7. [SEC Ownership Information: SINGER DAVID B](https://www.sec.gov/cgi-bin/own-disp?CIK=0001240366&action=getowner&sortid=filings-ASC)
---
*Topic: Encyclopedia › Society and history › Economics and business › Founders, operators, and investors › Venture and growth investors › Life-science venture and company creation › Biotech venture capital partners › Titles A to J*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026 · Edited: Oct 11, 2026; Oct 21, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license